EGFR inhibitors Oct 3, 2022 Theseus Pharmaceuticals to Develop Pan-EGFR Inhibitor for Resistant NSCLC Patients Sep 11, 2022 Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients Premium Aug 29, 2022 RedCloud Begins Phase I/IIa Trial in EGFR TKI-Resistant Lung Cancer Aug 25, 2022 AstraZeneca's Tagrisso, Lynparza Net Adjuvant Approvals in Japan Aug 11, 2022 New Drugs Going After 'Achilles' Heel' Resistance Mutation in NSCLC Premium Jul 29, 2022 AstraZeneca Q2 Oncology Sales Grow 14 Percent as Firm Awaits Key Precision Drug Regulatory Decisions Premium Jul 28, 2022 EGFR Exon 20 Insertion Location Could Be Key Factor in NSCLC Treatment Premium May 20, 2022 EQRx's Aumolertinib Bests AstraZeneca's Iressa in Head-to-Head NSCLC Trial Premium May 12, 2022 Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor May 9, 2022 Theseus Pharmaceuticals Addressing KIT, EGFR Resistance With Pan-Variant Inhibitors Premium Apr 26, 2022 Black Diamond Therapeutics to Discontinue ErbB Inhibitor Program, Lay Off 30 Percent of Workforce Apr 18, 2022 Black Diamond Therapeutics Doses First Patient in Recurrent EGFR-Mutant Glioblastoma, NSCLC Trial Apr 8, 2022 Blueprint Medicines Expands Trials of EGFR Inhibitors in NSCLC Mar 17, 2022 FDA Approves FoundationOne CDx for EGFR Inhibitors to Identify EGFR Mutations in NSCLC Mar 2, 2022 RedCloud Bio to Begin Trial of Fourth-Generation EGFR Inhibitor in NSCLC Subgroup Feb 9, 2022 Cyclica, University of Toronto Lab Launch Joint Venture Perturba Therapeutics Jan 31, 2022 Akeso Begins Phase III Trial of Bispecific Antibody, Chemo in EGFR-TKI Resistant NSCLC Jan 4, 2022 MSK, Amgen Explore Lumakras Combination Regimens to Overcome KRAS Inhibitor Resistance Premium Nov 29, 2021 Blueprint Medicines Acquires Lengo Therapeutics in $465M Deal Nov 24, 2021 Hutchmed, AstraZeneca Begin Phase III Trial in NSCLC With EGFR, MET Mutations Load More Breaking News Marengo Therapeutics Begins Phase I/II Trial of Selective T-Cell-Targeted Antibody Janssen, Legend Biotech's Carvykti Bests Chemo in Earlier-Line Multiple Myeloma Trial In Brief This Week: PreludeDx, Johnson & Johnson, Syros, Magenta, Merck NICE Backs Gilead Sciences' Yescarta as Third-Line Option for Lymphoma Patients BMS Eyeing Breyanzi Indications in CLL, SLL After Positive Trial Data Enhertu Approved in Europe for HER2-Low Metastatic Breast Cancer
